Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 381

1.

Aspirin to prevent heart attack and stroke: what's the right dose?

Dalen JE.

Am J Med. 2006 Mar;119(3):198-202. Review.

PMID:
16490462
2.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

3.

The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.

Hennekens CH, Schneider WR.

Expert Rev Cardiovasc Ther. 2008 Jan;6(1):95-107. Review.

PMID:
18095910
4.
5.

Aspirin in the prevention of strokes.

Diener HC.

Biomed Pharmacother. 1999 Aug;53(7):309-11. Review.

PMID:
10472429
6.

An update on aspirin in the primary prevention of cardiovascular disease.

Eidelman RS, Hebert PR, Weisman SM, Hennekens CH.

Arch Intern Med. 2003 Sep 22;163(17):2006-10.

PMID:
14504112
7.
8.

Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.

Gibson CM, Pride YB, Aylward PE, Col JJ, Goodman SG, Gulba D, Bergovec M, Kunadian V, Zorkun C, Buros JL, Murphy SA, Antman EM.

J Thromb Thrombolysis. 2009 Jan;27(1):11-7. doi: 10.1007/s11239-008-0264-4. Epub 2008 Aug 10.

PMID:
18695943
9.

Antithrombotic Secondary Prevention After Stroke.

Diener HC, Ringleb P.

Curr Treat Options Neurol. 2001 Sep;3(5):451-462.

PMID:
11487459
10.

Antithrombotic Secondary Prevention After Stroke.

Diener HC, Ringleb P.

Curr Treat Options Cardiovasc Med. 2002 Oct;4(5):429-440.

PMID:
12194815
11.

Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.

Berger JS, Brown DL, Becker RC.

Am J Med. 2008 Jan;121(1):43-9. doi: 10.1016/j.amjmed.2007.10.002. Review.

PMID:
18187072
12.

Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.

Teramoto T, Shimada K, Uchiyama S, Sugawara M, Goto Y, Yamada N, Oikawa S, Ando K, Ishizuka N, Yamazaki T, Yokoyama K, Murata M, Ikeda Y.

Am Heart J. 2010 Mar;159(3):361-369.e4. doi: 10.1016/j.ahj.2009.11.030.

PMID:
20211296
13.

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.

Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL; SPORTIF Investigators.

Am Heart J. 2006 Nov;152(5):967-73.

PMID:
17070169
14.

Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].

Kirshner HS.

Int J Clin Pract. 2007 Oct;61(10):1739-48. Review. Erratum in: Int J Clin Pract. 2007 Nov;61(11):1957.

15.
16.

[Aspirin dosage for prevention of cerebral infarct: arguments for low dosage].

Hennerici MG, Meairs S.

Nervenarzt. 1995 Dec;66(12):890-4; discussion 885. Review. German.

PMID:
8584072
17.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am Heart J. 1999 Apr;137(4 Pt 2):S9-S13. Review.

PMID:
10097241
18.

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.

Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, Moayyedi P, Forman D.

Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. Review.

20.

The role of aspirin in cardiovascular diseases--forgotten benefits?

Williams A, Hennekens CH.

Expert Opin Pharmacother. 2004 Jan;5(1):109-15. Review.

PMID:
14680440

Supplemental Content

Support Center